Concomitant bladder cancer and prostate cancer: Challenges and controversies

Antonio Lopez-Beltran, Liang Cheng, Francesco Montorsi, Maria Scarpelli, Maria R. Raspollini, Rodolfo Montironi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Radical cystoprostatectomy (RCP) followed by bilateral pelvic lymphadenectomy and urinary diversion remains the gold-standard therapy for men with localized muscle-invasive bladder cancer (MIBC). Prostate cancer might be incidentally detected at the time of RCP with a reported prevalence of 24-51%. Typically, these patients are considered to have clinically insignificant disease, but data from emerging series challenge this assumption and suggest that some of these tumours might be aggressive, or somehow increase the aggressiveness of the associated MIBC, and can negatively influence the patient's overall survival outcomes. Furthermore, the potential use of prostate-sparing cystectomy in patients with less-aggressive MIBC might lead to newly diagnosed incidental cases of prostate cancer, with characteristics suggestive of clinically significant disease, requiring a specific, separate workup. The development of evidence-based, validated protocols to define the necessary steps for diagnosis of prostate cancer in these patients, including the role of serum PSA testing, digital rectal examination, the role of imaging methods and the indication and type of biopsy protocol, is of major importance to the multidisciplinary management of patients with urological cancer. Finally, the retrospective nature of the available data account for much of the variability in the prevalence of coexisting bladder and prostate cancer and emphasizes the need for randomized trials in this controversial area of urological oncology.

Original languageEnglish (US)
Pages (from-to)620-629
Number of pages10
JournalNature Reviews Urology
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Urinary Bladder Neoplasms
Prostatic Neoplasms
Muscles
Urologic Neoplasms
Digital Rectal Examination
Urinary Diversion
Cystectomy
Lymph Node Excision
Gold
Prostate
Biopsy
Survival
Serum
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Lopez-Beltran, A., Cheng, L., Montorsi, F., Scarpelli, M., Raspollini, M. R., & Montironi, R. (2017). Concomitant bladder cancer and prostate cancer: Challenges and controversies. Nature Reviews Urology, 14(10), 620-629. https://doi.org/10.1038/nrurol.2017.124

Concomitant bladder cancer and prostate cancer : Challenges and controversies. / Lopez-Beltran, Antonio; Cheng, Liang; Montorsi, Francesco; Scarpelli, Maria; Raspollini, Maria R.; Montironi, Rodolfo.

In: Nature Reviews Urology, Vol. 14, No. 10, 01.10.2017, p. 620-629.

Research output: Contribution to journalReview article

Lopez-Beltran, A, Cheng, L, Montorsi, F, Scarpelli, M, Raspollini, MR & Montironi, R 2017, 'Concomitant bladder cancer and prostate cancer: Challenges and controversies', Nature Reviews Urology, vol. 14, no. 10, pp. 620-629. https://doi.org/10.1038/nrurol.2017.124
Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M, Raspollini MR, Montironi R. Concomitant bladder cancer and prostate cancer: Challenges and controversies. Nature Reviews Urology. 2017 Oct 1;14(10):620-629. https://doi.org/10.1038/nrurol.2017.124
Lopez-Beltran, Antonio ; Cheng, Liang ; Montorsi, Francesco ; Scarpelli, Maria ; Raspollini, Maria R. ; Montironi, Rodolfo. / Concomitant bladder cancer and prostate cancer : Challenges and controversies. In: Nature Reviews Urology. 2017 ; Vol. 14, No. 10. pp. 620-629.
@article{a721631d9a0b467b8dffc10f4f3905b8,
title = "Concomitant bladder cancer and prostate cancer: Challenges and controversies",
abstract = "Radical cystoprostatectomy (RCP) followed by bilateral pelvic lymphadenectomy and urinary diversion remains the gold-standard therapy for men with localized muscle-invasive bladder cancer (MIBC). Prostate cancer might be incidentally detected at the time of RCP with a reported prevalence of 24-51{\%}. Typically, these patients are considered to have clinically insignificant disease, but data from emerging series challenge this assumption and suggest that some of these tumours might be aggressive, or somehow increase the aggressiveness of the associated MIBC, and can negatively influence the patient's overall survival outcomes. Furthermore, the potential use of prostate-sparing cystectomy in patients with less-aggressive MIBC might lead to newly diagnosed incidental cases of prostate cancer, with characteristics suggestive of clinically significant disease, requiring a specific, separate workup. The development of evidence-based, validated protocols to define the necessary steps for diagnosis of prostate cancer in these patients, including the role of serum PSA testing, digital rectal examination, the role of imaging methods and the indication and type of biopsy protocol, is of major importance to the multidisciplinary management of patients with urological cancer. Finally, the retrospective nature of the available data account for much of the variability in the prevalence of coexisting bladder and prostate cancer and emphasizes the need for randomized trials in this controversial area of urological oncology.",
author = "Antonio Lopez-Beltran and Liang Cheng and Francesco Montorsi and Maria Scarpelli and Raspollini, {Maria R.} and Rodolfo Montironi",
year = "2017",
month = "10",
day = "1",
doi = "10.1038/nrurol.2017.124",
language = "English (US)",
volume = "14",
pages = "620--629",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Concomitant bladder cancer and prostate cancer

T2 - Challenges and controversies

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Montorsi, Francesco

AU - Scarpelli, Maria

AU - Raspollini, Maria R.

AU - Montironi, Rodolfo

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Radical cystoprostatectomy (RCP) followed by bilateral pelvic lymphadenectomy and urinary diversion remains the gold-standard therapy for men with localized muscle-invasive bladder cancer (MIBC). Prostate cancer might be incidentally detected at the time of RCP with a reported prevalence of 24-51%. Typically, these patients are considered to have clinically insignificant disease, but data from emerging series challenge this assumption and suggest that some of these tumours might be aggressive, or somehow increase the aggressiveness of the associated MIBC, and can negatively influence the patient's overall survival outcomes. Furthermore, the potential use of prostate-sparing cystectomy in patients with less-aggressive MIBC might lead to newly diagnosed incidental cases of prostate cancer, with characteristics suggestive of clinically significant disease, requiring a specific, separate workup. The development of evidence-based, validated protocols to define the necessary steps for diagnosis of prostate cancer in these patients, including the role of serum PSA testing, digital rectal examination, the role of imaging methods and the indication and type of biopsy protocol, is of major importance to the multidisciplinary management of patients with urological cancer. Finally, the retrospective nature of the available data account for much of the variability in the prevalence of coexisting bladder and prostate cancer and emphasizes the need for randomized trials in this controversial area of urological oncology.

AB - Radical cystoprostatectomy (RCP) followed by bilateral pelvic lymphadenectomy and urinary diversion remains the gold-standard therapy for men with localized muscle-invasive bladder cancer (MIBC). Prostate cancer might be incidentally detected at the time of RCP with a reported prevalence of 24-51%. Typically, these patients are considered to have clinically insignificant disease, but data from emerging series challenge this assumption and suggest that some of these tumours might be aggressive, or somehow increase the aggressiveness of the associated MIBC, and can negatively influence the patient's overall survival outcomes. Furthermore, the potential use of prostate-sparing cystectomy in patients with less-aggressive MIBC might lead to newly diagnosed incidental cases of prostate cancer, with characteristics suggestive of clinically significant disease, requiring a specific, separate workup. The development of evidence-based, validated protocols to define the necessary steps for diagnosis of prostate cancer in these patients, including the role of serum PSA testing, digital rectal examination, the role of imaging methods and the indication and type of biopsy protocol, is of major importance to the multidisciplinary management of patients with urological cancer. Finally, the retrospective nature of the available data account for much of the variability in the prevalence of coexisting bladder and prostate cancer and emphasizes the need for randomized trials in this controversial area of urological oncology.

UR - http://www.scopus.com/inward/record.url?scp=85030550834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030550834&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2017.124

DO - 10.1038/nrurol.2017.124

M3 - Review article

AN - SCOPUS:85030550834

VL - 14

SP - 620

EP - 629

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 10

ER -